About Endobetix
Endobetix is a company based in Misgav (Israel) founded in 2012 by Pierre Sharvit. It operates as a B2B. Endobetix has raised $2.5 million across 1 funding round from investors including The Trendlines Group. Endobetix operates in a competitive market with competitors including Fractyl, GI Dynamics, MetaModix, Allevetix and EndObetes, among others.
- Headquarter Misgav, Israel
- Founders Pierre Sharvit
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$2.5 M (USD)
in 1 rounds
-
Latest Funding Round
$2.5 M (USD), Series A
Oct 31, 2012
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Endobetix
Endobetix has successfully raised a total of $2.5M through 1 strategic funding round. The most recent funding activity was a Series A round of $2.5 million completed in October 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Endobetix
Endobetix has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include The Trendlines Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund and startup incubator for healthcare and agricultural companies
|
Locked | Locked | Locked |
Investor details for Endobetix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Endobetix
Investment portfolio details for Endobetix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Endobetix
Detailed financials for Endobetix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Endobetix Comparisons
Peer comparison for Endobetix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Endobetix
Endobetix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Fractyl, GI Dynamics, MetaModix, Allevetix and EndObetes, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Endoscopic procedures for type-2 diabetes treatment are developed.
|
|
| Locked | Locked | Locked |
Endoscopic barriers for diabetes and metabolic disease treatment are developed.
|
|
| Locked | Locked | Locked |
Endoscopically introduced bile diversion device
|
|
| Locked | Locked | Locked |
Developer of device for controlling hormonal balance
|
|
| Locked | Locked | Locked |
Surgical access tool for obesity and diabetes treatment is developed.
|
|
| Locked | Locked | Locked |
Non-invasive medical devices for diabetes treatment are developed.
|
Detailed competitors of Endobetix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Endobetix
Complete news archive for Endobetix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Endobetix
Endobetix was founded in 2012.
Endobetix is headquartered in Misgav, Israel. It is registered at Misgav, Northern District, Israel.
Chen Porat is the current CEO of Endobetix.
Endobetix is a funded company, having raised a total of $2.5M across 1 funding round to date.
Endobetix endobetix provides an endoscopically introduced device for bile diversion through providing healthcare solutions, developing medical devices, endoscopic solutions, and bile diversion devices. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
Endobetix's top competitors include Fractyl, GI Dynamics and EndObetes.
Endobetix has 1 investor. Key investors include The Trendlines Group.